Major Ingredients

(CefuroximeUSP 125 mg + Clavulanic Acid USP 31.25 mg)/5ml Suspension.

Major Functionality

It is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below : Pharyngitis/tonsillitis, Acute bacterial otitis media, Acute bacterial maxillary sinusitis, Acute bacterial exacerbations of chronic bronchitis and secondary bacterial infections of acute bronchitis, Uncomplicated skin and skin-structure infections, Uncomplicated urinary tract infections, Uncomplicated gonorrhea, Early lyme disease.

Manufacture Information

Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.